Introduction {#sec1}
============

Aplastic anemia is a rare hematologic disease characterized by bone marrow hypocellularity.[@bib1]^,^[@bib2] The profound reduction in hematopoietic stem/progenitor cells results in peripheral blood pancytopenia. The pathogenesis of aplastic anemia is still elusive.[@bib3] There is evidence that bone marrow mesenchymal stem cells (BMSCs) isolated from patients with aplastic anemia have a reduced osteogenic potential compared to BMSCs from healthy individuals.[@bib4]^,^[@bib5] In contrast, the adipogenic potential of BMSCs is increased in patients with aplastic anemia.[@bib6]^,^[@bib7] The reduction in the osteogenic capacity of BMSCs has been causally linked to the development of aplastic anemia.

The ten-eleven translocation (TET) family comprising three members (TET1, TET2, and TET3) is an important epigenetic modifier.[@bib8] TET proteins are capable of converting 5-methyl-cytosine (5-mC) to 5-hydroxymethyl-cytosine (5hmC), consequently leading to DNA demethylation.[@bib9] Previous studies reported that TETs play an essential role in stem cell differentiation.[@bib10]^,^[@bib11] For instance, Dawlaty et al.[@bib10] demonstrated that Tet1/2/3 triple knockout impairs the differentiation of mouse embryonic stem cells. Similarly, Yang et al.[@bib11] reported that loss of Tet1 and Tet2 blocks differentiation of BMSCs and leads to an osteoporotic phenotype in a mouse model. Cakouros et al.[@bib12] showed that TET2 functions as a promoter of both osteogenesis and adipogenesis. Most interestingly, *TET2* somatic mutations (7.3%) were frequently detected in patients with aplastic anemia.[@bib13] These studies encourage us to hypothesize that TETs may be implicated in the pathogenesis of aplastic anemia through regulation of the differentiation of BMSCs.

MicroRNAs (miRNAs) are endogenous, small, noncoding RNAs that regulate target gene expression at the post-transcriptional level through mRNA degradation or translational inhibition.[@bib14] The miRNA target sites are primarily detected in the 3′ untranslated region (UTR) of mRNAs.[@bib15] Previous studies have demonstrated that several miRNAs contribute to the lineage commitment of stem cells.[@bib16], [@bib17], [@bib18] For instance, miR-384-5p affects osteogenic differentiation of rat BMSCs by targeting Gli2.[@bib16] Our previous work has shown that miR-204 has the ability to regulate MSC differentiation in aplastic anemia.[@bib19] miR-144-3p is capable of inhibiting differentiation of C3H10T1/2 pluripotent stem cells to the osteoblast lineage.[@bib20] A recent study, published when a revised version of this manuscript was in preparation, has reported that miR-144-3p can inhibit osteogenic differentiation of BMSCs from patients with steroid-associated osteonecrosis.[@bib21] In contrast, miR-144-3p facilitates adipogenesis in 3T3-L1 pre-adipocytes.[@bib22] These findings suggest that miR-144-3p is a regulator of osteogenic and adipogenic differentiation.

Despite these advances, the pivotal miRNA regulators coordinating differentiation of BMSCs from patients with aplastic anemia are largely unknown. In the present study, we performed miRNA quantitative real-time PCR arrays to screen for differentially expressed miRNAs between BMSCs from patients with aplastic anemia and healthy controls. The role of miRNA candidates in regulating osteogenic differentiation of BMSCs was explored.

Results {#sec2}
=======

miR-144-3p Is Upregulated in BMSCs from Patients with Aplastic Anemia {#sec2.1}
---------------------------------------------------------------------

To identify novel regulators involved in the pathogenesis of aplastic anemia, we performed miRNA quantitative real-time PCR arrays in 3 independent samples to search for differentially expressed miRNAs between BMSCs from healthy controls and patients with aplastic anemia ([Figure 1](#fig1){ref-type="fig"}A). Among the 84 stem cell differentiation-related miRNAs tested, 4 miRNAs (i.e., miR-9, miR-125b, miR-144-3p, and miR-302) exhibited changes of greater than 4-fold ([Table S1](#mmc1){ref-type="supplementary-material"}). To validate the results of miRNA quantitative real-time PCR arrays, we measured the expression of the 4 candidate miRNAs by quantitative real-time PCR analysis in 23 patients with aplastic anemia and 18 healthy controls. As a result, we confirmed that miR-144-3p was significantly upregulated in BMSCs from patients with aplastic anemia relative to healthy equivalents ([Figure 1](#fig1){ref-type="fig"}B; p = 0.00054). However, no significant changes were noted in the expression of the other 3 candidate miRNAs (data not shown). These results suggest that miR-144-3p plays a major role in the biology of BMSCs from patients with aplastic anemia.Figure 1miR-144-3p Is Upregulated in BMSCs from Patients with Aplastic Anemia(A) Flow chart of the screening for differentially expressed miRNAs between BMSCs from healthy controls and patients with aplastic anemia. (B) Quantitative real-time PCR analysis of miR-144-3p expression in BMSCs from healthy controls (n = 18) and patients with aplastic anemia (n = 23).

miR-144-3p Inhibits the Osteogenic Potential of BMSCs from Patients with Aplastic Anemia {#sec2.2}
----------------------------------------------------------------------------------------

To determine the function of miR-144-3p in osteogenic differentiation of BMSCs, we knocked down miR-144-3p in BMSCs from patients with aplastic anemia. The knockdown efficiency was verified by quantitative real-time PCR analysis ([Figure 2](#fig2){ref-type="fig"}A). The miR-144-3p-depleted cells were cultured in osteogenic medium, and osteogenic differentiation was evaluated. Notably, the alkaline phosphatase (ALP) activity was significantly elevated in miR-144-3p-depleted cells ([Figure 2](#fig2){ref-type="fig"}B). Moreover, miR-144-3p deficiency markedly increased ALP and Alizarin Red staining ([Figures 2](#fig2){ref-type="fig"}C and 2D). miR-144-3p knockdown was associated with increased expression of osteoblast-specific genes *ALP* and osteocalcin ([Figure 2](#fig2){ref-type="fig"}E). However, miR-144-3p did not affect the adipogenic potential of BMSCs from patients with aplastic anemia (data not shown).Figure 2Knockdown of miR-144-3p Increases the Osteogenic Potential of BMSCs from Patients with Aplastic Anemia(A) Quantitative real-time PCR analysis of miR-144-3p expression in BMSCs transfected with anti-Ctrl or anti-miR-144-3p. (B) Measurement of ALP activity in BMSCs transfected with anti-Ctrl or anti-miR-144-3p after culturing in osteogenic medium. (C) ALP and Alizarin Red staining in BMSCs treated as in (B). Representative images are shown. (D) Quantification of Alizarin Red staining results. (E) Quantitative real-time PCR analysis of ALP and osteocalcin (OC) mRNA levels. n = 3 for each group in all experiments. \*p \< 0.05.

We also overexpressed miR-144-3p in BMSCs ([Figure 3](#fig3){ref-type="fig"}A) and tested their osteogenic potential. The results showed that ectopic expression of miR-144-3p led to reduced ALP and Alizarin Red staining after culturing in osteogenic medium ([Figure 3](#fig3){ref-type="fig"}B). Consistently, ALP activity ([Figure 3](#fig3){ref-type="fig"}C) and osteoblast marker gene expression ([Figure 3](#fig3){ref-type="fig"}D) were diminished in miR-144-3p-overexpressing BMSCs. Collectively, miR-144-3p serves as a repressor of osteogenic differentiation of BMSCs.Figure 3Overexpression of miR-144-3p Inhibits the Osteogenic Potential of BMSCs from Patients with Aplastic Anemia(A) Quantitative real-time PCR analysis of miR-144-3p expression in BMSCs transfected with miR-144-3p-expressing plasmid or empty vector. (B) ALP and Alizarin Red staining in BMSCs transfected with miR-144-3p-expressing plasmid or empty vector after culturing in osteogenic medium. (C) Measurement of ALP activity in BMSCs treated as in (B). (D) Quantitative real-time PCR analysis of ALP and osteocalcin mRNA levels. n = 3 for each group in all experiments. \*p \< 0.05.

miR-144-3p Negatively Regulates the Expression of TET2 in BMSCs {#sec2.3}
---------------------------------------------------------------

To identify direct target genes of miR-144-3p, we conducted an *in silico* analysis using the TargetScan tool. The results showed that several osteogenesis-related genes, including TET2, HOXA10, EZH2, FZD4, FOXO1, and PAX3, are predicted as miR-144-3p targets (data not shown). Overexpression of miR-144-3p led to a marked reduction of TET2 protein expression in BMSCs from patients with aplastic anemia ([Figure 4](#fig4){ref-type="fig"}A). Furthermore, TET2 mRNA levels were suppressed by overexpression of miR-144-3p ([Figure 4](#fig4){ref-type="fig"}B). However, the expression of HOXA10, EZH2, FZD4, FOXO1, and PAX3 remained unchanged after miR-144-3p overexpression ([Figure S1](#mmc1){ref-type="supplementary-material"}). In agreement with reduced TET2 expression, the total 5hmC level was significantly diminished by miR-144-3p overexpression ([Figure 4](#fig4){ref-type="fig"}C). In addition, depletion of miR-144-3p significantly increased the expression of TET2 ([Figures 4](#fig4){ref-type="fig"}A and 4B) and total 5hmC levels ([Figure 4](#fig4){ref-type="fig"}C) in BMSCs from patients with aplastic anemia.Figure 4miR-144-3p Negatively Regulates the Expression of TET2 in BMSCs(A) Western blot analysis of TET2 protein in BMSCs transfected with miR-144-3p-expressing plasmid or empty vector. (B) Quantitative real-time PCR analysis of TET2 mRNA levels in BMSCs treated as in (A). (C) Measurement of total 5hmC levels. (D) Bioinformatic prediction of miR-144-3p binding sites in the 3′ UTR of *TET2* mRNA. (E) Luciferase reporter assay showing that the luciferase reporter containing wild-type *TET2* 3′ UTR was repressed by miR-144-3p. Mutation of the miR-144-3p binding site impaired the miR-144-3p-mediated repression of the luciferase reporter. n = 3 for each group in all experiments. \*p \< 0.05. n.s. indicates no significance.

Next, we performed luciferase reporter assays to check whether miR-144-3p could directly target *TET2* mRNA. The 3′ UTR of *TET2* was predicted to contain putative miR-144-3p binding sites ([Figure 4](#fig4){ref-type="fig"}D). When the luciferase reporter containing wild-type *TET2* 3′ UTR was cotransfected with the miR-144-3p-expressing plasmid, the luciferase activity was reduced by 75% ([Figure 4](#fig4){ref-type="fig"}E). Elimination of the miR-144-3p responsive element impaired the suppressive effect of miR-144-3p ([Figure 4](#fig4){ref-type="fig"}E). Taken together, miR-144-3p shows the ability to repress the expression of TET2 in BMSCs from patients with aplastic anemia.

TET2 Mediates the Suppressive Effects of miR-144-3p on Osteogenesis {#sec2.4}
-------------------------------------------------------------------

Next, we tested whether miR-144-3p exerts anti-osteogenic effects through repression of TET2. Knockdown of TET2 ([Figure 5](#fig5){ref-type="fig"}A) remarkably prevented the osteogenic differentiation of BMSCs cultured in osteogenic medium, as evidenced by decreased ALP activity ([Figure 5](#fig5){ref-type="fig"}B) and *ALP* and osteocalcin expression ([Figure 5](#fig5){ref-type="fig"}C). We also performed rescue experiments by overexpressing TET2 cDNA lacking the 3′ UTR ([Figure 5](#fig5){ref-type="fig"}D). miR-144-3p-mediated inhibition of osteogenesis was relieved by ectopic expression of TET2 ([Figures 5](#fig5){ref-type="fig"}E and 5F). The results identify TET2 as a functional target of miR-144-3p in BMSCs from patients with aplastic anemia.Figure 5TET2 Mediates the Suppressive Effects of miR-144-3p on Osteogenesis(A) Western blot analysis of TET2 protein in BMSCs transfected with TET2-targeting siRNA (siTET2) or control siRNA (siCtrl). (B) Measurement of ALP activity in BMSCs transfected with siTET2 or siCtrl after culturing in osteogenic medium. (C) Quantitative real-time PCR analysis of ALP and osteocalcin mRNA levels. (D) Western blot analysis of TET2 protein in BMSCs transfected with TET2-expressing plasmid or empty vector. (E) Measurement of ALP activity in BMSCs transfected with indicated constructs after culturing in osteogenic medium. (F) Quantitative real-time PCR analysis of ALP and osteocalcin mRNA levels. n = 3 for each group in all experiments. \*p \< 0.05.

Correlation of the Expression of miR-144-3p and TET2 in BMSCs from Patients with Aplastic Anemia {#sec2.5}
------------------------------------------------------------------------------------------------

Finally, we explored the correlation in the expression of miR-144-3p and TET2 in aplastic anemia. Of note, there was a significant negative correlation between the expression of miR-144-3p and TET2 in BMSCs from patients with aplastic anemia (*r* = −0.5571, p = 0.0058; [Figure 6](#fig6){ref-type="fig"}A). These results suggest that the miR-144-3p/TET2 axis plays an important role in the biology of BMSCs from patients with aplastic anemia.Figure 6Correlation of the Expression of miR-144-3p and TET2(A) A significant negative correlation was noted between the expression of miR-144-3p and TET2 in BMSCs from patients with aplastic anemia (n = 23). (B) Schematic model of miR-144-3p-mediated suppression of osteogenesis in BMSCs.

Discussion {#sec3}
==========

Several lines of evidence have established a link between the reduced osteogenic potential of BMSCs and aplastic anemia.[@bib5]^,^[@bib6]^,^[@bib23] However, the underlying molecular mechanism remains unclear. In this work, we demonstrate that BMSCs from patients with aplastic anemia have a significantly higher level of miR-144-3p than those from healthy individuals. miR-144-3p is implicated in multiple biological processes, including tumorigenesis,[@bib24]^,^[@bib25] osteogenesis,[@bib20]^,^[@bib26] and adipogenesis.[@bib22] In particular, overexpression of miR-144-3p can block osteogenic differentiation and proliferation of murine MSCs by repressing Smad4.[@bib20] Wang et al.[@bib26] reported that miR-144-3p regulates bone homeostasis in patients with osteoporosis. Consistently, our results show that knockdown of miR-144-3p leads to increased osteogenesis of BMSCs from patients with aplastic anemia. We suggest that the increased expression of miR-144-3p may account for the impaired, reduced osteogenic potential of BMSCs in patients with aplastic anemia. Although miR-144-3p exhibits an ability to promote adipogenesis in 3T3-L1 mouse adipocyte precursors,[@bib22] we did not observe the regulation of adipogenesis of BMSCs from patients with aplastic anemia by miR-144-3p. The unexpected results may reflect that miR-144-3p effects depend on the cellular contexts. Despite these findings, an unbiased, systematic approach will be utilized to identify more miR regulators of osteogenic differentiation of BMSCs in aplastic anemia.

A number of target genes of miR-144-3p, such as Smad4 and FZD4, have been identified to mediate the inhibitory effects on osteogenic differentiation.[@bib20]^,^[@bib21] However, we did not observe the negative regulation of the 2 target genes in miR-144-3p-overexpressing BMSCs from patients with aplastic anemia ([Figure S2](#mmc1){ref-type="supplementary-material"}). We speculated that a novel mechanism is likely involved in the anti-osteogenic role of miR-144-3p in aplastic anemia. Intriguingly, we revealed that miR-144-3p selectively targets TET2, leading to a reduction of TET2 mRNA and protein expression in BMSCs from patients with aplastic anemia. TET2 functions as an epigenetic modifier and has the ability to regulate osteogenic lineage-associated genes.[@bib12] Aplastic anemia is associated with genetic instability, with frequent mutations in multiple genes, including *TET2*.[@bib13]^,^[@bib27] Huang et al.[@bib13] showed that there is a significant correlation between TET2 mutations and good response to immunosuppressive therapy in patients with aplastic anemia. Our data provide evidence for the post-transcriptional regulation of TET2 in aplastic anemia. We demonstrate that TET2 serves as a direct target of miR-144-3p in BMSCs from patients with aplastic anemia. Moreover, depletion of TET2 suppresses the osteogenic differentiation of BMSCs from patients with aplastic anemia. Rescue experiments further confirm that overexpression of TET2 reverses miR-144-3p-mediated inhibitory effects on osteogenesis. There is an inverse correlation between miR-144-3p and TET2 expression in aplastic anemia. These data indicate that TET2 plays an essential role in modulating the differentiation capacity of BMSCs, which may represent a mechanism for the involvement of TET2 in aplastic anemia.

The osteogenic markers ALP and osteocalcin can be epigenetically regulated during osteogenesis.[@bib28]^,^[@bib29] Liu et al.[@bib28] reported that treatment with 5-aza-2′-deoxycytidine, a DNA methyltransferase inhibitor, significantly increases the expression of osteogenesis-related genes in human periodontal ligament stem cells, resulting in enhanced osteogenic differentiation. Similarly, Delgado-Calle et al.[@bib29] found that the degree of methylation in the promoter of *ALP* is inversely associated with the transcriptional levels of ALP in the osteoblastic cell line MG-63. Our data show that miR-144-3p overexpression significantly diminishes the total 5hmC level in BMSCs from patients with aplastic anemia, which is accompanied by reduced expression of ALP and osteocalcin. In contrast, miR-144-3p knockdown increases total 5hmC levels and promotes the expression of ALP and osteocalcin. Taken together, miR-144-3p contributes to epigenetic regulation of osteogenic genes, likely mediated through repression of TET2 ([Figure 6](#fig6){ref-type="fig"}B).

In summary, our data indicate that miR-144-3p negatively regulates osteogenic differentiation of BMSCs from patients with aplastic anemia. The anti-osteogenic activity is causally linked to repression of TET2 and epigenetic modulation of osteogenic markers. Therefore, we suggest that the miR-144-3p/TET2 axis may be engaged in the progression of aplastic anemia.

Materials and Methods {#sec4}
=====================

Patients {#sec4.1}
--------

To screen for differentially expressed miRNAs, we enrolled 3 patients with aplastic anemia and 3 age- and sex-matched healthy individuals who had normal bone marrow findings. In the validation cohort, we included 23 patients with aplastic anemia (9 women, 14 men; ages 33 ± 4 years) and 18 healthy subjects (8 women, 10 men; ages 31 ± 3 years). For both cohorts, eligibility criteria were age ≥18 years and diagnosis of aplastic anemia (based on pancytopenia and hypocellular bone marrow). The patients who had other causes of hematological disorders were excluded. The study was approved by the Institutional Review Board at Henan Cancer Hospital (Zhengzhou, China). An informed consent was obtained from each subject.

BMSC Isolation and Cell Lines {#sec4.2}
-----------------------------

As described previously,[@bib19] mononuclear cells were isolated from bone marrow aspirates by Ficoll-Paque density gradient centrifugation (1.077 g/mL) and cultured in Dulbecco's modified Eagle medium (DMEM)/F12 (Invitrogen, Grand Island, NY, USA), supplemented with 10% fetal bovine serum (FBS; Invitrogen). After 72 h, nonadherent cells were discarded. Adherent cells were subcultured and used for further experiments. For immunophenotypic characterization, BMSCs were examined for the expression of CD45, CD34, CD105, CD73, and CD44 by flow cytometry.[@bib19]

HEK293T cells were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and cultured in DMEM, supplemented with 10% FBS.

Quantitative Real-Time PCR Analysis and miRNA Quantitative Real-Time PCR Arrays {#sec4.3}
-------------------------------------------------------------------------------

For analysis of mRNA levels, total RNA was isolated with TRIzol reagent (Invitrogen). Complementary DNA (cDNA) was synthesized with the RevertAid First Strand cDNA Synthesis kit (Thermo Fisher Scientific, Waltham, MA, USA). Quantitative real-time PCR was performed with the SYBR Premix Ex TaqII (Takara, Dalian, China), as per the manufacturer's instructions. The PCR primers are as follows: ALP: forward 5′-ACACCTTGACTGTGGTTACTG-3′ and reverse 5′-CCATATAGGATGGCCGTGAAG-3′; osteocalcin: forward 5′-AATAGCCCTGGCAGATTCCC-3′ and reverse 5′-CTCTCATGGTGTCTCGGTGG-3′; TET2: forward 5′-ACGCAAGCCAGGCTAAACA-3′ and reverse 5′-GCTGGGACTGCTGCATGA-3′; glyceraldehyde 3-phosphate dehydrogenase (GAPDH): forward 5′-GGATTTGGTCGTATTGGG-3′ and reverse 5′-GGAAGATGGTGATGGGATT-3′.[@bib30]^,^[@bib31] For detection of miR-144-3p, total RNA was isolated using the miRNeasy Mini Kit (QIAGEN, Hilden, Germany). Quantitative real-time PCR was performed using the miScript SYBR PCR Kit (QIAGEN) with the MystiCq microRNA qPCR Assay Primer (Sigma-Aldrich, St. Louis, MO, USA). U6 was used as an internal control. The relative expression was calculated by the 2^−ΔΔCt^ method.[@bib32]

For profiling of mature miRNAs, cDNA was added to the TaqMan Human Stem Cell miRNA PCR Array (Hanyu Biomed, Beijing, China), which contains specific primers for 84 stem cell-related miRNAs. The relative miRNA expression was determined after normalization to U6.

Plasmids and Oligonucleotides {#sec4.4}
-----------------------------

miR-144-3p inhibitor (anti-miR-144-3p) and negative control inhibitor (anti-Ctrl) were purchased from Thermo Fisher Scientific. TET2-targeting small interfering RNA (siRNA) was purchased from Sigma-Aldrich. The plasmids expressing mature miR-144-3p and TET2 were obtained from Hanyu Biomed. Wild-type 3′ UTR of *TET2* or its mutant version was cloned downstream of the firefly luciferase cDNA of pGL3 vector.

Cell Transfection {#sec4.5}
-----------------

BMSCs were seeded at 2 × 10^6^ cells per well in 6-well plates and incubated overnight at 37°C. Cell transfection was performed with indicated constructs (2 μg) using HiPerFect Transfection Agent (QIAGEN), according to the manufacturer's instruction. Twenty-four hours later, transfected cells were subjected to osteogenic differentiation and gene-expression analysis.

*In Vitro* Osteogenic Differentiation {#sec4.6}
-------------------------------------

As described previously,[@bib19] BMSCs were seeded in 6-well plates and cultured in DMEM/F12, supplemented with 10 mM β-glycerophosphate, 0.1 μM dexamethasone, and 0.2 mM ascorbic acid (Sigma-Aldrich) for 3 weeks.

ALP and Alizarin Red Staining {#sec4.7}
-----------------------------

For ALP staining, cells were fixed in 4% paraformaldehyde and stained with the ALP Staining Kit (Cell Biolabs, San Diego, CA, USA), following the manufacturer's protocol. For Alizarin Red staining, cells were fixed and stained with 1% Alizarin Red S (pH 4.2; Sigma-Aldrich). The Alizarin Red staining results were quantified by a spectrophotometer at 595 nm.

ALP Activity Assay {#sec4.8}
------------------

ALP activity was determined using the Colorimetric Alkaline Phosphatase Assay Kit (Abcam, Cambridge, MA, USA), as per the manufacturer's instructions. Absorbance was measured at 405 nm.

Western Blot Analysis {#sec4.9}
---------------------

Cells were lysed with radioimmunoprecipitation (RIPA) buffer (Sigma-Aldrich) on ice. Total protein concentration was determined using the Pierce Coomassie Plus Bradford assay kit, following the manufacturer's instructions (Thermo Fisher Scientific). Proteins were resolved by 10% SDS-PAGE and electrotransferred onto a nitrocellulose membrane. After blocking with 5% bovine serum albumin, the membrane was incubated with rabbit anti-TET2 polyclonal antibody (1:300 dilution; Sigma-Aldrich) or anti-GAPDH polyclonal antibody (1:2,000 dilution; Abcam) overnight at 4°C. The membrane was then incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit immunoglobulin G (IgG) for 1 h at room temperature. Signals were visualized with an Amersham enhanced chemiluminescence (ECL) detection system (GE Healthcare, Cambridge, MA, USA). Densitometry was performed using Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA).

Dual-Luciferase Reporter Assay {#sec4.10}
------------------------------

A luciferase reporter assay was conducted, as described previously.[@bib33] HEK293T cells were cotransfected with TET2 3′ UTR luciferase reporters, together with miR-144-3p-expressing plasmid or empty vector. 48 hours later, the cells were harvested and tested for firefly and *Renilla* luciferase activities using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA), according to the manufacturer's instructions. Firefly luciferase activity was normalized to that of *Renilla* luciferase.

Quantification of Total 5hmC Levels {#sec4.11}
-----------------------------------

Total 5hmC levels were measured using the Quest 5hmC DNA ELISA kit (Zymo Research, Irvine, CA, USA), as described previously.[@bib34] In brief, genomic DNA was extracted from cells using the Universal Genomic DNA Extraction Kit (Takara). An anti-5hmC polyclonal antibody was diluted and added to the wells of assay plates. Genomic DNA was denatured and added to the coated wells at a final concentration of 100 ng/well. The mixture was incubated at 37°C for 1 h. After incubation with HRP-conjugated secondary antibody, substrate solution was added and colors developed. Absorbance was recorded at 405 nm.

Statistical Analysis {#sec4.12}
--------------------

Data are expressed as the mean ± standard deviation. Differences between groups were analyzed using the Student's t test, one-way analysis of variance, or Mann-Whitney U test. The correlation between miR-144-3p and TET2 expression was assessed with Spearman's correlation analysis. Values of p \< 0.05 were considered significant.
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